Clinical DevelopmentGH001 showed impressive reduction in depression scores in the Phase 2b trial for treatment-resistant depression, with a significant number of patients achieving remission.
Financial PositionWith a cash position of $315.3M, GH is well positioned to drive GH001 into late-stage development and expand into additional high-need psychiatric indications.
Regulatory ProgressGH remains on track to submit a full response to the FDA to address the investigational new drug (IND) hold on GH001, a key regulatory milestone that could enable U.S. entry into a pivotal Phase 3 program.